The Technical Analyst
Nuvectis Pharma, Inc. [NVCT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Nuvectis Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.18% $6.59
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 117.10 mill |
| EPS: | -1.430 |
| P/E: | -4.61 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 17.77 mill |
| Avg Daily Volume: | 0.0954 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.61 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.78x |
| Company: PE -4.61 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.229 (-81.34%) $-5.36 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.58 - 7.60 ( +/- 15.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Bentsur Ron | Buy | 5 000 | Common Stock |
| 2024-01-03 | Poradosu Enrique | Buy | 130 000 | Common Stock |
| 2024-01-03 | Shemesh Shay | Buy | 130 000 | Common Stock |
| 2023-10-10 | Bentsur Ron | Buy | 640 | Common Stock |
| 2023-10-09 | Bentsur Ron | Buy | 830 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 100 transactions |
| Buy: 1 056 063 | Sell: 0 |
Forecast:
16:00 - $6.60
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.60
Forecast 2: 16:00 - $6.60
Forecast 3: 16:00 - $6.60
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.59 (-7.18% ) |
| Volume | 0.0393 mill |
| Avg. Vol. | 0.0954 mill |
| % of Avg. Vol | 41.25 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVCT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Latest Press Releases
2024-04-08 08:30:00 - Press Release
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity In Non-small Cell Lung Cancer Cell Lines
Highly synergistic antiproliferative activity in egfr-resistant cells in combination with osimertinib, the active ingredient in tagrissotm single agent antiproliferative activity in cells resistant to alectinib, the active ingredient in alecensatm fort lee, nj, april 08, 2024 (globe newswire) -- nuvectis pharma, inc. (nasdaq: nvct) today recapped poster highlights from the 2024 american association for cancer research (aacr) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (egfr)-resistant non-small cell lung cancer (nsclc) cells of nxp900 in combination with osimertinib, the active ingredient in tagrissotm, an egfr inhibitor approved for the treatment of nsclc...
2024-03-19 08:00:00 - Press Release
Nuvectis Pharma Announces Upcoming Presentations At The 2024 American Association For Cancer Research Meeting
Fort lee, nj, march 19, 2024 (globe newswire) -- nuvectis pharma, inc. (nasdaq: nvct) ("nuvectis" or the "company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for nxp800 and nxp900 at the upcoming 2024 american association for cancer research meeting (2024 aacr), taking place from april 5th to april 10th in san diego, california. presentation details are below:
2024-03-15 08:00:00 - Press Release
Nuvectis Pharma To Present At The 36th Annual Roth Conference
Fort lee, nj, march 15, 2024 (globe newswire) -- nuvectis pharma, inc. (“nuvectis”, “company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that ron bentsur, chairman and chief executive officer, will present at the 36th annual roth conference.
2024-03-14 09:00:00 - Press Release
Nuvectis Pharma Announces Encouraging Preliminary Data From The Nxp800 Phase 1b Clinical Trial In Platinum-resistant Arid1a-mutated Ovarian Cancer
33% response rate and 100% disease control rate observed in patients evaluated for efficacy complete response of non-target tumor also observed platinum-resistant ovarian cancer is a devastating serious condition of unmet medical need with a median life expectancy of approximately one year fort lee, nj, march 14, 2024 (globe newswire) -- nuvectis pharma, inc. (nasdaq: nvct) today announced preliminary data from the ongoing phase 1b clinical trial of nxp800 in patients with platinum resistant arid1a-mutated ovarian cancer, a deadly disease of unmet medical need. the nxp800 development program in this disease was granted fast track designation by the u.s. food and drug administration (“fda”).
2024-03-05 08:00:00 - Press Release
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results And Business Highlights
Fort lee, n.j., march 05, 2024 (globe newswire) -- nuvectis pharma, inc. (nasdaq: nvct) ("nuvectis" or the "company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the fiscal year 2023 and provided an update on recent business progress.
Latest News
2024-04-02 16:30:04 - InvestorPlace
5 Healthcare Stocks to Buy for 2024
What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.
2024-03-15 08:00:00 - GlobeNewsWire
Nuvectis Pharma to Present at the 36th Annual Roth Conference
FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.
2024-02-09 08:32:00 - GlobeNewsWire
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
2024-02-09 08:00:00 - GlobeNewsWire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
2024-01-03 08:00:00 - GlobeNewsWire
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:
2023-10-16 11:18:38 - Zacks Investment Research
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-09-25 19:30:00 - GlobeNewsWire
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:
2023-09-06 08:03:53 - Seeking Alpha
Nuvectis: Early Stage Company That's Low On Cash
Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, including in cisplatin resistant patients. NVCT also has a second asset, NXP900, which has shown significant single-agent activity in squamous cell cancer models.
2023-09-01 08:00:00 - GlobeNewsWire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
2023-07-10 08:44:07 - Zacks Investment Research
New Strong Buy Stocks for July 10th
CRBG, LSF, SMWB, NVCT and WT have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2023.